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Background: the aim of this study was to systematically review the literature for studies that investigated the effects 
of sclerosing agents on head and neck hemangiomas. 
Material and Methods: clinical trials, cohort studies, and descriptive studies were considered eligible and selected 
in a two-phase process. Six main electronic databases, in addition to three grey literature databases, were searched. 
Risk of bias (RoB) was assessed using the “Meta-Analysis of Statistics Assessment and Review Instrument” chec-
klist. From fifty-six considered eligible, five were finally included. 
Results: one article were judged at low, one at moderate, and three at high RoB. The sclerosing agents investigated 
were sodium tetradecyl sulphate (n=2), ethanolamine oleate (n=1), pingyangmycin (n=1) and bleomycin (n=1). Ove-
rall, good results were achieved on the treatment of head and neck hemangiomas with intralesional sclerotherapy. 
Most commonly reported adverse effects included pain, swelling, fever, necrosis, transient facial palsy, and anorexia. 
Conclusions: considering the limited number of included studies, intralesional sclerotherapy on the management of 
HN hemangiomas presented overall good results with minor adverse reactions, especially in regards to smaller lesions.




Vascular anomalies comprise a heterogeneous group of 
lesions that have been classified by the International So-
ciety for the Study of Vascular Anomalies (ISSVA) into 
vascular malformations and vascular tumors (1). He-
mangioma is a common type of benign vascular tumor 
that usually affects newborns and infants, although in 
some cases it might persist into adulthood (2). It should 
be mentioned that misdiagnosed of vascular tumors and 
vascular malformations is still recurrent and this can 
lead to misconduct, therefore, caution should be exerci-
sed regarding assessment of these conditions.
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Approximately 10-12% of children at 1 year of age are 
affected by this condition (2) and nearly 60% of heman-
giomas are located in the head and neck (HN) region, (3-
5) specially the face, oral mucosa, lips, and tongue (2,4). 
Some subsets of hemangioma have been documented. 
Congenital hemangiomas (CH) are fully formed at birth 
and according to its clinical course, can be subdivided 
into two major subgroups: rapidly involuting congeni-
tal hemangioma (RICH) and noninvoluting congenital 
hemangioma (NICH) (6).  The first one rapidly regress 
within 3 to 5 months and the second remains static in 
their clinical course (7).
Infantile hemangiomas (IH) are the most common be-
nign vascular tumor of childhood and differs from CH 
in histologic features and immunophenotype, as well as 
clinical presentation and behavior (7). At birth, IH often 
appears as a precursor lesion, such as an area of telan-
giectasia or small purple area, then increases and become 
more recognizable. A fast growth occurs at three to five 
months; thereafter it usually involutes in several year, al-
though abnormal texture, color, or residual fibroadipose 
tissue might persist on the overlying skin (3,8).  
About 50% of hemangiomas have a complete resolution 
in 5 years and 70% in 7 years. Most of the lesions are 
small and usually no treatment is indicated (9). Howe-
ver, treatment is often indicated for those large lesions 
that present rapid growth, located in cosmetically areas, 
or presenting complications, such as ulceration, pain, 
bleeding, secondary infection, and tissue deformation 
(3,4,10). Possible psychosocial consequences on the 
affected child and family should also be considered with 
regard to treatment decisions (11).
To date, there is yet no consensus on the treatment of he-
mangiomas. Nonetheless, surgical excision is no longer 
the first choice (4) since it is related with complications 
such as bleeding, scarring, organ and tissue dysfunction 
(12), nerve damage (13), and often results in residual 
pathology (5). Still, many nonsurgical treatments have 
been attempted, including systemic propranolol and cor-
ticosteroids, interferon-α, lasertherapy, embolization, 
cryotherapy, radiotherapy, intralesional sclerotherapy, 
among others (10). Sclerosing agents applied intrale-
sionally promotes lesion reduction and sclerosis (13). 
However, a wide range of sclerosing agents have been 
documented and its effectiveness and safety remains un-
clear (13).
The aim of this systematic review (SR) was to investigate 
the effectiveness and safety of sclerosing agents on HN 
hemangiomas and provide to physicians and dental cli-
nicians an evidence-based therapeutic decision-making.
Material and Methods
A SR protocol was registered at Prospective Register of 
Systematic Reviews under the registration number CRD 
42018100394 (14). The reporting of this SR was based 
on PRISMA recommendations (15). The acronym PI-
COS (Population, Intervention, Comparison, Outcome, 
Studies) was used to formulate the question of this study, 
of which: P) individuals diagnosed with HN hemangio-
mas; I) intralesional sclerotherapy; C) other therapies, 
placebo, or pre-treatment status; O) lesion size reduction 
and complications; and S) clinical trials, cohort studies, 
or case-series with at least 10 participants. Only articles 
published in Latin Roman alphabet were considered.
The following exclusion criteria were applied: 1) studies 
that evaluated animals; 2) case-series with less than 10 
participants with HN hemangiomas; 3) studies that com-
bined sclerosing agents with other therapies; 4) studies 
investigating sclerosing therapy for vascular malforma-
tions or that did not provide separate data for heman-
giomas; 5) studies investigating sclerosing therapy for 
peri- or intra-orbital vascular tumors; 6) studies in which 
outcomes for different sclerosing agents or different le-
sion sites were not reported separately; 7) abstracts, re-
views, case-reports, protocols, laboratory research; 8) 
studies not published in the Latin Roman alphabet; and 
9) full-text not available.
Search strategies were elaborated for the following 
electronic databases: Embase, Latin American and Ca-
ribbean Health Sciences (LILACS), PubMed, SCOPUS, 
The Cochrane Library, and Web of Science. In addition, 
a grey literature search was conducted on Google Scho-
lar, Open Grey, and ProQuest. All searches were perfor-
med from the starting coverage date through May 12, 
2019. Detailed search strategies are provided in Table 
1, 1 continue. 
Furthermore, following the recommendation by Green-
halgh and Peacock (16), reference lists of included studies 
were hand-searched to assess relevant references. Refe-
rence management and removal of duplicates were per-
formed using software (EndNote X7, Thomson Reuters).
The selection process was performed in two phases. 
Phase-1 was carried out in a web application (Rayyan®, 
Qatar Computing Research Institute). Firstly, two blin-
ded reviewers (R.T.S and F.M.S.) screened title and 
abstracts of all identified studies and discrepancies were 
resolved by a consensus discussion; if necessary, a third 
reviewer was involved (G.M.). Thereafter, the same re-
viewers applied the eligibility criteria to full-text arti-
cles; if a consensus was not achieved, the third reviewer 
was consulted. Studies were included for analysis if mi-
nimum inclusion criteria were met.
Two blinded reviewers (R.T.S. and F.M.S.) collected 
data from included studies; information was then cross-
checked to warrant integrity of contents. Gathered data 
consisted of study characteristics, population characte-
ristics, intervention characteristics, outcome measures, 
and adjustment factors.
Risk of bias (RoB) was independently assessed by two 
reviewers (R.T.S. and F.M.S.) using the Joanna Briggs 
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Institute Meta-Analysis of Statistics Assessment and 
Review Instrument (MAStARI), specific for descriptive 
studies. A third reviewer (G.M.) was involved in case 
of disagreements. Studies were categorized as “high” 
when reaching up to 49% score “yes”; “moderate” when 
reaching 50% to 69% score “yes”; and “low” when the 
study reached more than 70% score “yes”. 
Lesion size reduction and occurrence of collateral effects 
related to sclerotherapy (e.g. pain, ulceration, fever, 
hypo or hyperpigmentation, and others) were evaluated 
by means of absolute or relative differences between ba-
seline and follow-up evaluations. In order to standardize 
results, values were described in percentage.
Results
The search strategy, after removing duplicates, resulted 
in 1239 records. Following title and abstract screening, 
fifty-six articles were considered eligible for full-text 
reading, of which 51 were excluded with reasons accor-
dantly to eligibility criteria (Table 2, 2 continue). There-
after, five studies were included for qualitative analysis 
(Fig. 1).
Reference Author (year) Reasons for Exclusion*
1. Ali 2016 4
2. Araújo 2016 9
3. Baud 2000 9
4. Carramaschi 1991 9
5. Crawford 2009 4
6. Fernandes 2018 6
7. Fraulin 2012 4
8. Gelbert 2000 4
9. Govrin-Yehudain 1987 6
10. Guo 2014 8
11. Gupta 2017 6
12. Han 2016 8
13. Hassan 2013 6
14. He 2007 8
15. Hintringer 2009 3
16. Hiraoka 2012 6
17. Hou 2008 8
18. Huang 2006 8
19. Jianhong 2005 3
20. Jiménez 2009 6
21. Johann 2005 6
22. Kane 1995 6
23. Lameiro 2018 2
24. Liu GJ 2013 8
25. Liu SH 1980 8
26. Liu XJ 2009 4
27. Liu XJ 2001 8
28. Luo 2011 3
29. Muir 2004 6
30. Pandey 2018 3
31. Qin 2002 8
32. Qin 1995 8
33. Qiu 2015 6
34. Ribeiro 2015 6
Table 2: Articles excluded and the reasons for exclusion (n=51).
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35. Sachin 2013 6
36. Sainsbury 2011 6
37. Saxena 2013 9
38. Shou 2000 8
39. Shou 1996 8
40. Tai 2015 8
41. Thakral 2013 2
42. Thayal 2012 3
43. Wang, C 2000 8
44. Wang, L 2009 8
45. Wang, Y 2012 9
46. Winter 2000 6
47. Woods 1987 2
48. Yang 2009 3
49. Zhang 2016 3
50. Zheng 1991 8
51. Zhou 2002 8
Table 2 continue: Articles excluded and the reasons for exclusion (n=51).
Fig. 1: Flow diagram of literature search and selection criteria (adapted from Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analysis and generated 
using the software Review Manager 5.3, The Cochrane Collaboration).
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All included articles were descriptive studies, of which 
4 were prospective case-series (5,17-19) and 1 a retros-
pective study (20). One study was conducted in China 
(5), one in India (17), one in Brazil (20), one in Sou-
th Africa (19), and 1 in Israel (18). Most studies were 
written in English (5,17-19) and 1 in Portuguese (20). 
Sample size ranged from 13 (20) to 66 (5) participants. 
Participants’ age ranged from 2 months (5) to 79 years 
(18). Only 1 study did not provide any information con-
sidering adverse reactions (20). More information about 
study characteristics is available in Table 3, 3 continue, 
3 continue-1.
Overall, one study were judged at low, one at modera-
te, and 3 at high RoB. No included study investigated 
randomized or pseudo-random populations; however, 
this was expected since participants must present benign 
HN hemangiomas. Regarding confounders, three studies 
provided detailed description of methods (5,17,19), whi-
lst 2 did not provide sufficient information to permit a 
clear judgment (18,20). Moreover, two studies used ob-
jective outcome measures, whilst others used subjective 
measures (17,18,20). It should be noted that only 2 stu-
dies carried out an appropriate follow-up (5,19). More 
information regarding RoB assessment is available in 
Figure 2. 
-Results of individual studies
Agarwal et al. (2011) (17) investigated the effect of in-
tralesional STS 3% on hemangiomas of the tongue, lip, 
and palate in 20 participants (mean age not reported). 
Total regression was observed in 19 (95%) individuals, 
whilst partial regression was observed in a single case 
(5%). Pain and mild local inflammatory reaction were 
observed in all cases, sloughing and ulceration in 2 
(10%), and palatal perforation in 1 case (5%).
Minkow et al. (1979) (18) studied the effect of STS 3% 
on hemangiomas located in the lips, tongue, palate, and 
cheek mucosa in 24 participants (mean age 37.9 years). 
Overall, total remission was observed after a single 
application in small tumors (0-1.5 cm), whilst larger tu-
mors (2-4 cm) required from 2 to 10 applications. No 
scars or defects were observed after treatment, howe-
ver, most individuals (frequency not reported) presented 
pain and swelling and 2 (8.3%) had pronounced inflam-
matory reaction.
Prado et al. (2011) (20) evaluated the therapeutic effect 
of intralesional EO (concentration not specified) on ge-
neric reported hemangiomas located in the lips, cheek, 
and tongue in 13 participants (mean age 62 years). Total 
regression was observed in all cases, although number 
of applications differed. A single application was requi-
red in 5 (38.5%) participants, whilst 3 (23.1%) required 
2 applications, four (30.8%) required 3 applications, and 
in 1 individual (7.7%), four applications were required. 
Side effects were not reported in this study.
Pienaar et al. (2006) (19) assessed the effect of intrale-
sional bleomycin (0.3 to 0.6 mg/kg) on hemangiomas 
in 30 individuals (mean age 20 months). From these, 
twenty-six (86.7%) individuals had lesions located in 
the cheeks, scalp, nose, lips, or eyelids. All individuals 
received 4 to 6 applications. Response-rates (rates hi-
gher than 90% were considered complete involution) 
regarding HN lesions were as follows: cheeks (83%), 
scalp (90%), nose (71%), lips (86%), and eyelids (90%). 
It should be noted that adverse reactions were not sepa-
rately reported for HN lesions and that 4 (13.3%) indivi-
duals had lesions in other anatomical sites. Nevertheless, 
hyperpigmentation was observed in 13 (43.3%) indivi-
duals, hypopigmentation in 5 (16.7%), and scarring in 4 
(13.3%). 
Hou et al. (2011) (5) investigated the effectiveness of 
intralesional pingyangmycin (1 mg/ml) on infantile he-
mangiomas of the forehead, nose, cheek, parotid/mas-
seteric area, and lip in 66 individuals (mean age 5.6 
months). The number of applications ranged from 1 to 
6 and follow-up time from 1 to 4 years, occurring every 
6 months. Complete cure of lesions was observed in 49 
(74%) individuals, whilst 9 (14%) had substantial im-
provements, and 8 (12%) showed mild improvements. 
Adverse reactions observed were local swelling (fre-
quency not reported), fever lower than 38oC in indivi-
duals 14 (21.2%), and anorexia in 8 (12.1%).
-Synthesis of results 
Clinical and methodological heterogeneity across studies 
were considered high. Since few studies were included 
and different substances and therapeutic protocols were 
observed, statistical pooling of data using meta-analysis 
was not considered appropriate.
Considering different sclerosing agents observed, two 
studies investigated STS 3% (17,18), one EO (20), one 
assessed bleomycin A5 hydrochloride in the concentra-
tion of 0.3 to 0.6 mg/kg (19), and 1 study evaluated pin-
gyangmycin (1 mg/ml) (5). 
Most studies presented good results for sclerotherapy re-
garding lesion reduction. Total remission in all participants 
was reported by Prado et al. (2011) (20) and Minkow et al. 
(1979) (18), whilst total remission or major improvements 
were reported by Agarwal et al. (2011) (17), Hou et al. 
(2011) (5), and Pienaar et al. (2006) (19). The number of 
applications varied according to the size of lesion.
The following side-effects were reported across studies: 
pain (17,18); swelling (5,18); sloughing, ulceration, and 
palatal perforation (17); fever (5); anorexia (5); hyper/
hypopigmentation (19); scarring (19); and local inflam-
mation (17,18). The follow-up times were considerably 
discrepant, with a minimum follow-up of three months 
(19) and maximum of four years (5).
Discussion
Sclerotherapy on the management of hemangiomas 
has been a topic of interest in several studies as they 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































are considered a conservative method and are usually 
well tolerated. Still, the literature is sparse considering 
its effectiveness. This SR was performed to synthesize 
data gathered and guide clinical conducts and further 
researches regarding this topic. It was observed that, 
considering lesion remission, intralesional sclerotherapy 
presented overall good results with minor side effects. 
Nonetheless, evidence was considered weak and further 
controlled trials and objective outcome measurements 
are recommended.
In this SR, the studies of Agarwal et al. (2011) (17) and 
Minkow  et al. (1979) (18) investigated STS 3%, of 
which total remission was observed in all (18) or in the 
majority of participants (17). STS is detergent sclero-
sant that produce endothelial damage through multiple 
mechanisms leading to thrombosis and fibrosis (21,22). 
This agent is considered to be less aggressive than ab-
solute ethanol and has been used to treat HN vascular 
lesions (21). 
Commonly reported adverse reactions in included stu-
dies investigating STS 3% were pain, swelling, local 
inflammatory reaction, sloughing, ulceration and pala-
tal perforation (17,18). These findings are in accordance 
with current literature since swelling, pain, discoloration 
of the lesion, ulcer (23), and also fever and rashes (24) 
are common adverse reactions observed. The most re-
ported side effect is tissue hyperpigmentation, although 
it is probably associated with use of inappropriately high 
concentrations or unexpectedly fragile veins. It should 
be highlighted that tissue necrosis has also been reported 
after administration of recommended doses, nonethe-
less, use of more dilute preparations of STS can lead to 
comparable results with decreased risk of necrosis (22).
Furthermore, a single included study (20) evaluated 
intralesional sclerotherapy with EO and, although evi-
dence was considered weak, total remission of the le-
sions were observed in all participants. EO is a detergent 
agent (21) that acts as sclerosant through endothelium 
damage, leading to thrombosis and fibrosis (12,25). The 
effectiveness of EO is proposed to be similar to STS and 
safer compared to ethanol (21). No adverse effects were 
reported in the study of Prado et al. (2011) (20).
Still, since data were collected from charts, gaps in in-
formation about treatment outcomes might be present. 
Nonetheless, most commonly reported adverse effects 
of EO in current literature are redness, inflammation, 
pain during injection, tissue necrosis, and anaphylaxis 
(25). Although the study of da Silva et al. (2014) (12) 
was excluded due to insufficient number of participants, 
EO was used to treat oral hemangiomas and only a local 
burning sensation was reported as a side effect during 
administration.
Regarding other sclerosing agents, one study investi-
gated the effects of bleomycin A5 hydrochloride (19). 
Bleomycin is a chemotherapeutic agent and, because of 
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Fig. 2: Risk of bias summary, assessed by the Joanna Briggs Institute Meta-Analysis of Statistics Assessment and 
Review Instrument (MAStARI): author’s judgments for each included study (generated using the software Review 
Manager 5.3, The Cochrane Collaboration). 
its thrombogenicity capability, it has also been used in 
sclerotherapy (21). In the study of Pienaar et al. (2006) 
(19) bleomycin was used to treat hemangiomas. This 
agent showed good response-rates, including in lesions 
larger than 20 cm. 
The collateral effects reported were hyperpigmenta-
tion, hypopigmentation, and scarring. Known collateral 
effects caused by bleomycin A5 are edema, ulceration, 
scarring, nausea, lack of appetite (26) and tissue atrophy 
(27). Soft tissue atrophy is partly attributed to necrosis, 
although it might affect normal cells as well, and beco-
mes more evident as the child grow up, since the tissue 
fails to grow (27). This collateral effect may be related to 
high dose or concentration of the sclerosing agent (27).
A single included study (5) investigated Pingyangmy-
cin to treat IH with maximum size of 4.6 cm x 3.8 cm, 
showing good results and few adverse reactions. Pyng-
yangmycin has a chemical structure similar to bleomy-
cin, acting by damaging endothelial cells, which leads to 
collapse, shrinkage, and fibrosis of target tissues (27 68).
There are many available options to treat HN heman-
giomas, including surgery, systemic drugs (e.g. propa-
nolol, atenolol, steroids), laser (4,28), topical drugs (e.g. 
imiquimod), ultrasound (28), as well as sclerotherapy or 
just a follow-up (21), still there is not a gold standard. 
In cases of IH that are life-threatening, such as lesions 
obstructing the airway, systemic propranolol is conside-
red the first choice of treatment (29). This method is also 
indicated in cases of existing or imminent functional im-
pairment, ulceration, pain, and bleeding, as well as the 
risk of long-term or permanent disfigurement (30).
Propanolol is non-cardioselective blocker of beta-adre-
ner¬gic receptors. It is proposed that propranolol inhi-
bits vasodilation via beta-receptors, which decreases 
blood flow to the lesion; blocks the release of proangio-
genic factors (e.g., VEGF, bFGF, MMP-2, and MMP-9), 
thus limiting the growth of IH; and induces apoptosis in 
endothelial cells, favoring tumor remission (30).
 Although propranolol is considered a conservative treat-
ment, risk of systemic effects should be highlighted. The 
most common non-serious events related to oral propra-
nolol are sleep disturbances, diarrhea, and constipation. 
Moreover, serious complications may occur, such as 
hypoglycemia or related seizure, bradycardia, hypoten-
sion, atrioventricular disturbances, and bronchospasm/ 
bronchial hyperreactivity (29). Due to potential systemic 
effects, topical administration has been suggested. A SR 
showed that good responses in size reduction with mini-
mal side effects (itching and erythema) can be achieved, 
although treatment success might be related to longer 
treatment durations (31).
In this SR, primary studies were considerably hetero-
geneous, especially regarding methods. Since different 
sclerosing agents were used, no direct comparison could 
be performed. Moreover, results should be interpreted 
with caution, as the magnitude of observed effects might 
be overestimated due to lack of control groups. Therefo-
re, athough overall good results were observed, further 
clinical studies with controlled design, standardized me-
thods, and objective outcome measurements are recom-
mended to better explore this topic. 
Within the limitations of this SR, intralesional sclerothe-
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rapy with STS 3%, EO, bleomycin, and pyngyamicin on 
the management of HN hemangiomas presented overall 
good results with minor adverse reactions, especially in 
regards to smaller lesions.
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